Your browser is no longer supported. Please, upgrade your browser.
ARPO [NASD]
Aerpio Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-0.09 Insider Own0.70% Shs Outstand47.17M Perf Week7.41%
Market Cap54.90M Forward P/E- EPS next Y-0.39 Insider Trans-6.07% Shs Float45.16M Perf Month-7.20%
Income-4.30M PEG- EPS next Q-0.10 Inst Own46.60% Short Float2.35% Perf Quarter-42.00%
Sales15.00M P/S3.66 EPS this Y82.30% Inst Trans1.27% Short Ratio0.81 Perf Half Y-15.94%
Book/sh0.91 P/B1.27 EPS next Y-18.20% ROA-9.80% Target Price1.75 Perf Year86.08%
Cash/sh0.90 P/C1.29 EPS next 5Y- ROE-10.40% 52W Range0.70 - 2.31 Perf YTD18.37%
Dividend- P/FCF- EPS past 5Y30.90% ROI-14.70% 52W High-52.16% Beta1.67
Dividend %- Quick Ratio24.00 Sales past 5Y- Gross Margin- 52W Low57.86% ATR0.08
Employees12 Current Ratio24.00 Sales Q/Q- Oper. Margin- RSI (14)41.59 Volatility9.73% 6.28%
OptionableNo Debt/Eq0.00 EPS Q/Q8.70% Profit Margin-28.80% Rel Volume1.03 Prev Close1.16
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume1.30M Price1.11
Recom2.00 SMA20-2.00% SMA50-17.49% SMA200-22.35% Volume537,370 Change-4.74%
Dec-09-20Initiated BTIG Research Buy $4
Jul-23-18Initiated Needham Buy $10
Apr-01-21 07:51AM  
07:08AM  
Mar-18-21 12:00PM  
Mar-11-21 08:00AM  
Mar-05-21 09:28AM  
08:00AM  
Feb-13-21 01:41AM  
Jan-14-21 10:46AM  
Jan-12-21 10:27AM  
10:04AM  
Jan-06-21 09:48AM  
09:24AM  
Jan-05-21 04:01PM  
Jan-04-21 09:34AM  
Dec-31-20 08:49AM  
Dec-30-20 11:25AM  
Dec-28-20 10:00AM  
Dec-24-20 09:14AM  
Dec-23-20 10:06AM  
Dec-22-20 10:22AM  
Dec-21-20 10:13AM  
Dec-18-20 11:15AM  
Dec-16-20 01:31PM  
Dec-15-20 10:54AM  
09:57AM  
Dec-14-20 01:04PM  
12:59PM  
12:00PM  
Dec-11-20 05:00PM  
08:34AM  
Dec-10-20 09:40AM  
Dec-09-20 08:45AM  
08:33AM  
Dec-08-20 08:56AM  
Dec-07-20 09:27AM  
09:27AM  
09:13AM  
Dec-04-20 08:45AM  
08:32AM  
08:29AM  
Dec-03-20 09:06PM  
10:23AM  
Nov-15-20 07:21AM  
Nov-10-20 08:00AM  
Nov-05-20 04:01PM  
04:01PM  
Oct-26-20 05:06PM  
04:01PM  
Sep-17-20 07:00AM  
Sep-15-20 08:30AM  
Sep-01-20 04:30PM  
04:30PM  
Aug-17-20 11:06AM  
Aug-12-20 08:00AM  
Aug-10-20 08:00AM  
Aug-05-20 07:35AM  
Aug-04-20 04:15PM  
Jun-29-20 05:50PM  
11:30AM  
Jun-24-20 08:00AM  
Jun-22-20 07:24AM  
Jun-19-20 05:45PM  
12:37PM  
Jun-15-20 10:07AM  
08:32AM  
Jun-12-20 11:30AM  
Jun-08-20 04:44PM  
09:00AM  
Jun-05-20 08:46AM  
May-29-20 09:59AM  
07:22AM  
May-27-20 04:30PM  
11:30AM  
May-26-20 07:49AM  
May-21-20 12:00PM  
08:01AM  
May-13-20 07:40AM  
May-12-20 04:30PM  
May-11-20 11:30AM  
May-07-20 08:00AM  
May-06-20 05:45PM  
Apr-24-20 07:24AM  
Apr-22-20 05:50PM  
11:30AM  
Apr-20-20 10:46AM  
Apr-16-20 08:39AM  
Apr-09-20 06:35AM  
Apr-08-20 12:00PM  
Mar-16-20 08:00AM  
Mar-12-20 05:00PM  
Feb-09-20 09:49AM  
Feb-07-20 06:20PM  
Jan-08-20 08:43AM  
Dec-22-19 05:08PM  
Nov-11-19 06:59AM  
Nov-07-19 07:00AM  
Oct-21-19 11:09AM  
05:00AM  
Oct-10-19 02:30PM  
Oct-09-19 09:00AM  
Aerpio Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing compounds that activate Tie2 for the treatment of ocular disease and vascular stabilization. The company's lead product candidate is razuprotafib, a small molecule inhibitor of vascular endothelial protein tyrosine phosphatase , which has completed phase IIb clinical trial for the treatment of non-proliferative diabetic retinopathy, as well as has completed phase II clinical trial for the treatment of patients with open angle glaucoma/ocular hypertension. It also develops ARP-1536, a humanized monoclonal antibody that is in preclinical development stage for the treatment of diabetic vascular complications, including nephropathy and diabetic macular edema; and bispecific antibody for the treatment for wet age-related macular degeneration and DME through intravitreal injection. Aerpio Pharmaceuticals, Inc. has a licensing and collaboration agreement with Gossamer Bio, Inc. for the development and commercialization of GB004, a selective stabilizer of hypoxia-inducible factor-1 alpha, which has completed Phase 1b clinical trial for the treatment of inflammatory bowel disease. The company is headquartered in Cincinnati, Ohio.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
ORBIMED ADVISORS LLC10% OwnerDec 08Sale1.9621,40041,9440Dec 10 05:04 PM